CA2713193C - A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression - Google Patents

A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression Download PDF

Info

Publication number
CA2713193C
CA2713193C CA2713193A CA2713193A CA2713193C CA 2713193 C CA2713193 C CA 2713193C CA 2713193 A CA2713193 A CA 2713193A CA 2713193 A CA2713193 A CA 2713193A CA 2713193 C CA2713193 C CA 2713193C
Authority
CA
Canada
Prior art keywords
seq
tucap
cells
protein
tm9sf4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2713193A
Other languages
English (en)
French (fr)
Other versions
CA2713193A1 (en
Inventor
Francesco Lozupone
Stefano Fais
Original Assignee
Exosomics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exosomics SpA filed Critical Exosomics SpA
Publication of CA2713193A1 publication Critical patent/CA2713193A1/en
Application granted granted Critical
Publication of CA2713193C publication Critical patent/CA2713193C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2713193A 2008-01-25 2009-01-26 A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression Active CA2713193C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6245308P 2008-01-25 2008-01-25
US61/062,453 2008-01-25
PCT/EE2009/000001 WO2009092385A1 (en) 2008-01-25 2009-01-26 A new metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Publications (2)

Publication Number Publication Date
CA2713193A1 CA2713193A1 (en) 2009-07-30
CA2713193C true CA2713193C (en) 2018-01-02

Family

ID=40527972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713193A Active CA2713193C (en) 2008-01-25 2009-01-26 A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Country Status (12)

Country Link
US (1) US8097407B2 (https=)
EP (1) EP2245465B1 (https=)
JP (1) JP5752419B2 (https=)
CN (1) CN102016587B (https=)
AU (1) AU2009207926B2 (https=)
BR (1) BRPI0906681A2 (https=)
CA (1) CA2713193C (https=)
ES (1) ES2587055T3 (https=)
MX (1) MX2010008163A (https=)
PL (1) PL2245465T3 (https=)
RU (1) RU2546000C2 (https=)
WO (1) WO2009092385A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122118A1 (en) * 2008-01-25 2012-05-17 Primm Srl Monclonal antibodies, hybridomas and methods for use
EP2467392A4 (en) * 2009-08-17 2013-06-19 Nox Technologies Inc CLONING AND EXPRESSION OF 9-DOMAIN SUPERFAMILY OF ARNOX TRANSMEMBRANE PROTEINS, METHODS AND UTILITY
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
WO2015185730A2 (en) * 2014-06-06 2015-12-10 Hansabiomed Ou Exosomal biomarkers
CN105675378A (zh) * 2014-11-18 2016-06-15 上海张江转化医学研发中心有限公司 一种简单的分离单个循环肿瘤细胞的方法和装置
JP6573351B2 (ja) 2017-05-29 2019-09-11 国立大学法人神戸大学 検出対象の分析用センサ作製用基材、検出対象の分析用センサ、及び検出対象の分析法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175787A1 (en) * 1997-10-28 2003-09-18 Incyte Corporation Vesicle membrane proteins
US20030008356A1 (en) * 1998-08-07 2003-01-09 Ono Pharmaceutical Co., Ltd. Novel polypeptide, a cDNA encoding the same, and use of it
WO2000008056A1 (fr) * 1998-08-07 2000-02-17 Ono Pharmaceutical Co., Ltd. NOUVEAU POLYPEPTIDE, ADNc LE CODANT ET SON UTILISATION
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer

Also Published As

Publication number Publication date
EP2245465A1 (en) 2010-11-03
AU2009207926B2 (en) 2014-06-19
PL2245465T3 (pl) 2016-11-30
US20090191222A1 (en) 2009-07-30
RU2546000C2 (ru) 2015-04-10
EP2245465B1 (en) 2016-05-18
MX2010008163A (es) 2011-04-26
JP5752419B2 (ja) 2015-07-22
ES2587055T3 (es) 2016-10-20
JP2011511625A (ja) 2011-04-14
US8097407B2 (en) 2012-01-17
CN102016587B (zh) 2015-05-13
CA2713193A1 (en) 2009-07-30
RU2010135525A (ru) 2012-02-27
BRPI0906681A2 (pt) 2019-11-26
WO2009092385A1 (en) 2009-07-30
CN102016587A (zh) 2011-04-13
AU2009207926A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US7998689B2 (en) Detection of CXADR protein for diagnosis of kidney cancer
US7521195B1 (en) Lung disease targets and uses thereof
US9658232B2 (en) Methods and compositions for treating and diagnosing diseases
US7807392B1 (en) Lung disease targets and uses thereof
Lozupone et al. The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells
CA2713193C (en) A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression
US20090196873A1 (en) Methods and compositions for treating diseases targeting CDCP1
US20120122118A1 (en) Monclonal antibodies, hybridomas and methods for use
US7611703B1 (en) Kidney disease targets and uses thereof
US20070059757A1 (en) Method and compositions for the treating diseases targeting E-cadherin
US20070065448A1 (en) Methods and compositions for treating diseases targeting MABA1
WO2006022682A2 (en) Method and compositions for treating diseases targeting cd49b
US8507213B1 (en) Methods and compositions for treating diseases targeting maba
US20060035239A1 (en) Method and compositions for treating diseases targeting CD51
TWI392504B (zh) 用於診斷及／或治療卵巢癌之抗原多肽
US20060039907A1 (en) Method and compositions for treating diseases targeting CD71
JPWO2006082851A1 (ja) エピグリカニン関連ムチン
WO2006022690A1 (en) Method and compositions for treating diseases targeting cd71
WO2006038904A2 (en) Method and compositions for treating diseases targeting e-cadherin

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251022

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318